Literature DB >> 12557150

Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat.

Yuji Iimuro1, Toshihiro Nishio, Taisuke Morimoto, Takashi Nitta, Branko Stefanovic, Sung Kyu Choi, David A Brenner, Yoshio Yamaoka.   

Abstract

BACKGROUND & AIMS: During hepatic fibrogenesis, the hepatic extracellular matrix changes to fibrillar collagens types I and III, and cirrhosis is believed to produce an irreversible scar. In this study, we investigated whether gene delivery of human matrix metalloproteinase-1, which degrades collagens types I and type III, would attenuate established hepatic fibrosis in the rat, induced by either thioacetamide or bile duct ligation.
METHODS: Hepatic fibrosis induced by thioacetamide for 7 weeks was persistent for at least 2 months, even after discontinuation of the treatment. The rats were infected once with a recombinant adenovirus, Ad5MMP-1, into which human pro-human matrix metalloproteinase-1 complementary DNA was packaged, or with a control adenovirus, Ad5LacZ.
RESULTS: In Ad5MMP-1-infected, but not in Ad5LacZ-infected, rats, the fibrosis was dramatically attenuated at 2 weeks after the infection. It is interesting to note that the number of activated hepatic stellate cells was also decreased in Ad5MMP-1-infected rats. Moreover, disorganization of the hepatic trabecula, heterogeneity in the size of hepatocytes, and increased dried liver weight were observed only in Ad5MMP-1-treated rats, suggesting that human matrix metalloproteinase-1 stimulated hepatocyte proliferation, which was confirmed by bromodeoxyuridine staining. After 4 weeks, the proliferative effect of human matrix metalloproteinase-1 almost disappeared, but the hepatic fibrosis remained attenuated, whereas the fibrosis in Ad5LacZ-treated rats persisted. Furthermore, the administration of Ad5MMP-1, but not Ad5LacZ, decreased type I collagen and generated a small collagen fragment in hepatic fibrosis induced by bile duct ligation.
CONCLUSIONS: Our findings show that transient human matrix metalloproteinase-1 overexpression in the liver effectively attenuates established fibrosis and induces hepatocyte proliferation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12557150     DOI: 10.1053/gast.2003.50063

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  75 in total

Review 1.  Targeting collagen expression in alcoholic liver disease.

Authors:  Kyle J Thompson; Iain H McKillop; Laura W Schrum
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

Review 2.  Cirrhosis: new research provides a basis for rational and targeted treatments.

Authors:  John P Iredale
Journal:  BMJ       Date:  2003-07-19

Review 3.  Timeline for development of autologous bone marrow infusion (ABMi) therapy and perspective for future stem cell therapy.

Authors:  Shuji Terai; Haruko Tanimoto; Masaki Maeda; Junichi Zaitsu; Takuro Hisanaga; Takuya Iwamoto; Koichi Fujisawa; Yuko Mizunaga; Toshihiko Matsumoto; Yohei Urata; Yoshio Marumoto; Isao Hidaka; Tsuyoshi Ishikawa; Yuichiro Yokoyama; Koji Aoyama; Masako Tsuchiya; Taro Takami; Kaoru Omori; Naoki Yamamoto; Makoto Segawa; Koichi Uchida; Takahiro Yamasaki; Kiwamu Okita; Isao Sakaida
Journal:  J Gastroenterol       Date:  2012-04-05       Impact factor: 7.527

Review 4.  Matrix metalloproteinases, the pros and cons, in liver fibrosis.

Authors:  Yuan-Ping Han
Journal:  J Gastroenterol Hepatol       Date:  2006-10       Impact factor: 4.029

Review 5.  Gene modulation for treating liver fibrosis.

Authors:  Kun Cheng; Ram I Mahato
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

6.  Matrix metalloproteinase-9, -10, and -12, MDM2 and p53 expression in mouse liver during dimethylnitrosamine-induced oxidative stress and genomic injury.

Authors:  Ismail Syed; Jasmine Rathod; Mayur Parmar; George B Corcoran; Sidhartha D Ray
Journal:  Mol Cell Biochem       Date:  2012-03-23       Impact factor: 3.396

7.  Mutations in the catalytic domain of human matrix metalloproteinase-1 (MMP-1) that allow for regulated activity through the use of Ca2+.

Authors:  Rudolph D Paladini; Ge Wei; Anirban Kundu; Qiping Zhao; Louis H Bookbinder; Gilbert A Keller; H Michael Shepard; Gregory I Frost
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

8.  Matrix metalloproteinase-1 promotes muscle cell migration and differentiation.

Authors:  William Wang; Haiying Pan; Kiley Murray; Bahiyyah S Jefferson; Yong Li
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

9.  Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma.

Authors:  Maria-Grazia Spiga; Teresa Borrás
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

Review 10.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.